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The Journal of Immunology
KIR3DL1/S1 Allotypes Contribute Differentially to the
Development of Behc¸et Disease
Harry Petrushkin,*,† Paul J. Norman,‡ Emma Lougee,x Peter Parham,{ Graham R. Wallace,‖
Miles R. Stanford,# and Farida Fortune†
Behc¸et disease is a chronic, relapsing-remitting autoinflammatory syndrome with a strong HLA-B*51 association. In this paper,
we describe a human cohort of 267 individuals with Behc¸et disease and 445 matched controls from a tertiary referral center in the
U.K. HLA-B*51 was confirmed as a genetic risk factor in this group (p = 0.0006, Bonferroni–Dunn correction for multiple testing
[Pc] = 0.0192, odds ratio [OR] 1.92, 95% confidence interval [CI] 1.33–2.76). KIR3DL1/S1 allele-level analysis indicated that low-
expressing KIR3DL1/S1 alleles in combination with KIR3DS1 increased the risk of developing Behc¸et disease (KIR3DL1LOW/
KIR3DS1: p = 0.0004, Pc = 0.0040, OR 2.47, 95% CI 1.43–4.25), whereas high-expressing KIR3DL1/S1 alleles in combination with
a null-expressing KIR3DL1 reduced the risk of disease (KIR3DL1HIGH/KIR3DL1NULL: p = 0.0035, Pc = 0.0350, OR 0.53, 95% CI
0.33–0.87). Behc¸et disease can manifest as a purely mucocutaneous disease or can involve other organ systems such as the eyes. In
the U.K. cohort studied in this study, KIR3DL1LOW/KIR3DS1 increased the risk of ophthalmic disease (p = 1.2 3 1025, OR 3.92,
95% CI 2.06–7.47), whereas KIR3DL1HIGH/KIR3DL1NULL reduced the risk of having purely mucocutaneous disease (p = 0.0048,
OR 0.45, 95% CI 0.25–0.81). To our knowledge, this is the first analysis of KIR3DL1/S1 allelic variation in Behc¸et disease and may
provide insight into the pathogenic role of HLA-B*51 and its interaction with KIR3DL1/S1. The Journal of Immunology, 2019,
203: 000–000.
B
ehc¸et disease (BD) is a chronic autoinflammatory,
relapsing-remitting, multisystemic syndrome. It is char-
acterized by orogenital ulcers, papulopustular and ery-
thema nodosum-like skin lesions, uveitis, retinal vasculitis,
thrombophlebitis, arterial aneurysms, and arthritis. BD is found
primarily along the ancient Silk Route from the Mediterranean
Basin across Asia to Japan, but cohorts have also been reported
in Northern Europe, North America, and South America (1). The
prevalence of BD across the Middle East and Asia is 20–400 per
100,000 (2–4). Recent data from the U.K. BD Centres of Ex-
cellence in 2017 suggest the incidence in the United Kingdom is
likely to be at least 2 per 100,000 (H. Petrushkin and F. Fortune,
unpublished observations), an increase on previous estimates (5),
suggesting the impact of this disease is underrecognized in in-
dividuals of European extraction.
BD has a genetic basis, with the strongest association loci residing
within the HLA-B region on chromosome 6 and with HLA-B*51
in particular. Evidence for this association was first described in
1982, when Ohno et al. observed that HLA-Bw51 (now HLA-
B*51) was associated with BD in Japanese patients. Recent
meta-analyses have shown HLA-B*51 carriage increases the risk
of BD by a factor of six. Eight genome-wide association studies
(GWAS) investigating BD have been carried out that support
single nucleotide polymorphisms in noncoding regions located
between the HLA-A–HLA-F loci, with considerable interstudy
heterogeneity regarding other reported associations (6, 7).
These GWAS have mainly been carried out in patients from
regions of the world where BD is most prevalent (Turkey,
Japan, China, Korea, Italy, and Iran), although in 2015, a mixed
population of patients with BD from the Netherlands was
reported (6, 8–14).
To date, the mechanistic association between HLA-B*51 and
disease pathogenesis remains unclear. HLA class I molecules
present Ag to CD8 cytotoxic T cells; however, there is little evi-
dence for a role of these cells in BD. Certain HLA class I mole-
cules are also ligands for the killer Ig-like receptor (KIR)
molecules expressed on NK cells. KIR3DL1, a polymorphic in-
hibitory receptor, interacts with HLA-B*51 via the Bw4 epitope, a
region spanning residues 77–83 on the a1 helix of certain HLA-A
and -B allotypes (15, 16). KIR3DL1 is an inhibitory receptor
encoded by multiple alleles of the KIR3DL1/S1 gene, whereas
KIR3DS1 is a conserved, activating receptor encoded at the same
locus. KIR3DS1 is primarily thought to interact with HLA-F
(17–20). The KIR gene cluster has only recently been defined at
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a high resolution, and disease-specific associations with KIR al-
lotypes are limited (21–24).
Previously, Middleton et al. (25) examined Turkish patients
with BD for the presence/absence of KIR3DL1/S1 but found
no association after controlling for the effects of HLA-B*51.
Erer et al. (26) studied a large, carefully compiled dataset of
1799 Turkish BD patients and reported an association between
KIR3DS1 and ocular disease, but no effect of KIR3DL1/S1
overall on disease risk. More recently, Mohammad-Ebrahim
et al. (27) examined 397 Iranian patients with BD but found
no specific KIR gene to be associated with BD. At present, there
are no studies that analyze KIR3DL1/S1 allelic variation or their
effect in BD. In this study, we set out to characterize HLA-A, -B,
and KIR3DL1/S1 genotype frequencies in a cohort of BD pa-
tients from the United Kingdom.
Materials and Methods
Patients
Two hundred sixty-seven individuals with BD and four hundred forty-five
demographically matched healthy controls (HC) were recruited from the
BD Centre of Excellence at the Royal London Hospital of Bart’s Health
National Health Service Trust (London, U.K.). All patients gave written
consent, and the project was approved by the local research ethics service
of the City and East London (P/03/122). The study conformed to the
Declaration of Helsinki. All patients fulfilled the Behcet Disease Interna-
tional Study Group diagnostic criteria (28). Samples were collected be-
tween 2013 and 2015. Individuals in the HC group were not related to
individuals in the BD group, and every effort was made to match the two
groups for sex and ethnicity. To avoid recruiting controls with undiagnosed
BD, all HC were over 40 y old because it is uncommon for BD to manifest
past the fourth decade.
Genotyping
Blood samples were collected in 10ml EDTA tubes, and DNAwas extracted
with QIAamp DNA Blood Maxi Kits (QIAGEN, Hilden, Germany). DNA
was eluted in AE buffer and stored at 280˚C until use. HLA-B and
KIR3DL1/S1 genes were sequenced using a Fluidigm library preparation
(Fluidigm, South San Francisco, CA). Amplicons were designed to span
the coding DNA sequence of HLA-B and KIR3DL1/S1 (primers available
upon request). Sequencing was carried using a MiSeq platform (Illumina,
San Diego, CA) at the Bart’s and the London Genome Centre (Bart’s and
the London Medical School, Charterhouse Square, London, U.K.). HLA-B
alleles were assigned using NGSengine software (GenDx, Utrecht, the
Netherlands), and KIR3DL1/S1 alleles were assigned using the Pushing
Immunogenetics to the Next Generation pipeline (29).
HLA-A typing
HLA-A genotyping was carried out using sequence-specific oligonucleotide
probes (Immucor, Peachtree Corners, GA) on a Luminex platform
(Luminex, Austin, TX) at the Viapath Clinical Transplantation Labora-
tory at Guys Hospital (London, U.K.).
Statistical analysis
Probabilities for categorical data were calculated using a two-tailed Fisher
exact test. Nonparametric, ordinal data were analyzed with a Mann–
Whitney U test. Differences between groups were calculated using a two-
way ANOVA. The Bonferroni–Dunn correction for multiple testing (Pc)
was applied (GraphPad Prism 7, GraphPad Software, La Jolla, CA). Where
the frequency of an outcome was 0, the Haldane correction was used to
estimate the odds ratio (OR) and 95% confidence intervals (CI). The
magnitude of the effect was estimated using the OR and 95% CI.
For 80% power with an a = 0.05, assuming a 1:2 case/control recruit-
ment, we aimed to collect at least 199 cases and 398 controls. This was
based on the population prevalence of KIR3DL1*001 in the United
Kingdom of 15% (30). As the exact KIR3DL1/S1 allele frequencies within
a United Kingdom–based BD cohort have not been explored, we collected
as many samples as possible to allow for patients withdrawing from the
study and technical problems with samples.
A p value #0.05 was considered to be statistically significant but only
in the context of a 95% CI that did not cross 1.00. If p , 0.05 but Pc .
0.05 and the 95% OR did not cross 1, the result was considered relevant
for discussion.
Results
The group demographics, including self-reported ethnicity, are
presented in Table I. There are no significant differences between
the sex or ethnicity of the cases and controls. The control group
was, on average, 13 y older than the BD group. The population
analyzed in this paper is of mixed ethnicity with 67.4% being of
self-reported Northern European ancestry. Clinical manifestations
along with the ethnicity of the patient groups are given in Fig. 1.
After quality control, HLA-A genotypes were obtained for 260
(97.38%) cases and 426 (95.73%) controls, HLA-B genotypes
were obtained for 266 (99.63%) cases and 443 (99.55%) controls,
and KIR3DL1/S1 genotypes were obtained for 256 (95.88%) cases
and 433 (97.30%) controls.
Association of HLA-B*51 with BD is replicated in the
U.K. cohort
HLA-B*51 was associated with BD (p = 0.0006, Pc = 0.0192, OR
1.92, 95% CI 1.33–2.76). A smaller effect was also identified for
HLA-B*08 (p = 0.0238, Pc = NS, OR 1.49, 95% CI 1.06–2.11),
HLA-A*25 (p = 0.0121, Pc=NS, OR 2.51, 95% CI 1.17–5.41), and
HLA-A*26 (p = 0.0291, Pc = NS, OR 1.76, 95% CI 1.00–3.10). A
suggestion of protective effects was found for HLA-B*58
(p = 0.0248, Pc = NS, OR 0.21, 95% CI 0.05–0.90), and
HLA-A*33 (p = 0.0131, Pc = NS, OR 0.45, 95% CI 0.22–0.92)
(Table II).
The HLA class I data were analyzed for the presence/absence of
Bw4, and the gene dosage of Bw4 encoding alleles was calculated
(i.e., an individual may have a maximum of four Bw4 encoding
alleles if both alleles of HLA-A and -B encode HLA allotypes with
the Bw4 epitope such as HLA-A*23/A*24 and HLA-B*51/B*44).
The results indicate that there was no disease association between
the presence/absence or gene dosage of Bw4 encoding alleles and
BD (data not shown).
KIR3DL1/S1 “functional genotypes” are associated with BD
Having established that HLA-B*51 conferred a risk of BD in this
cohort of patients, we investigated the effects of KIR3DL1/S1
allelic variation. KIR3DL1 was present in 96% of individuals in
both groups. There was no difference in the frequency of
KIR3DL1/S1 heterozygotes between the groups and no associa-
tion between the KIR3DL1/S1 presence/absence, and BD was
identified. Nor was there any departure from Hardy–Weinberg
Table I. Patient and HC demographics
Control (n) BD (n) p Value
Participants 445 267 —
Sex
Male 191 108 NS
Female 254 159 NS
Age 54 (IQ-range
54–58)
41 (IQ-range
36–43)
p , 0.0001
Ethnicity (self-reported)
Northern European 302 180 NS
Middle Eastern 39 31 NS
South Asian 40 15 NS
Sub-Saharan-African 2 6 NS
Southern European 13 6 NS
East Asian 12 4 NS
Mixed ethnicity 31 23 NS
North African 6 2 NS
The cases and controls were matched for gender and ethnicity. The control group
was selected to be over 50 y of age as BD usually manifests in the first five decades of
life. This was done to ensure no individuals with an unmasked autoinflammatory
disease were incorrectly labeled as healthy.
IQ, interquartile.
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Equilibrium between the BD and HC groups (Supplemental
Table I). We then analyzed our disease cohorts to ascertain
whether any individual KIR3DL1/S1 allele increased or de-
creased the risk of developing BD (Supplemental Table III);
KIR3DL1*005 and KIR3DS1*013 were found to contribute to-
ward the risk of disease, but the association did not survive
correction for multiple testing.
We grouped KIR3DL1/S1 allotypes by their expression phe-
notype based on previously published data (31–36). to create
functional genotypes. For those allotypes in which functional
data were not available, we assigned a presumptive expression
phenotype based on the nearest KIR3DL1/S1 allotypes for which
there is data (Supplemental Table II). We found no association be-
tween high-expressing KIR3DL1 (KIR3DL1HIGH), low-expressing
KIR3DL1 (KIR3DL1LOW), KIR3DL1 retained intracellularly
(KIR3DL1NULL), or the activating allele, KIR3DS1 (data not
shown). In contrast, we found the combination of KIR3DL1LOW/
KIR3DS1 was associated with BD (p = 0.0004, Pc = 0.0040, OR
2.47, 95% CI 1.43–4.25), whereas the combination of KIR3DL1HIGH/
KIR3DL1NULL was associated with protection from disease
(p = 0.0035, Pc = 0.0350, OR 0.53, 95% CI 0.33–0.87) (Table III).
The increased and decreased risk conferred by KIR3DL1LOW/
KIR3DS1 and KIR3DL1HIGH/KIR3DL1NULL, respectively, remained
when we removed those alleles without direct evidence of their
expression level (Supplemental Table IV). These results indicate
that the KIR3DL1LOW/KIR3DS1 functional genotype is associ-
ated with the risk of developing BD, whereas the KIR3DL1HIGH/
KIR3DL1NULL functional genotype is associated with protection
from BD.
We then analyzed the allelic composition of the implicated func-
tional genotypes. There were two genotypes associated with BD:
KIR3DL1*0050101LOW/KIR3DS1*0130101 (p = 0.0210, OR 1.91,
95% CI 1.07–3.43) and KIR3DL1*0070101LOW/KIR3DS1*0130101
(p = 0.0008, OR 15.22, 95% CI 1.92–120.87). Conversely,
KIR3DL1*0010101HIGH/KIR3DL1*00401NULL (p = 0.0172, OR 0.36,
95% CI 0.15–0.89) was found to be protective (Table IV).
To examine whether the KIR3DL1/S1 functional genotypes
conferring risk and protection are associated with BD or merely
the presence of Bw4/HLA-B*51, we repeated the above analysis,
controlling for these variables. We found the effect of possessing a
KIR3DL1LOW/KIR3DS1 risk genotype to be significant in all
groups except the HLA-B*51+ individuals. The protective effects
of the KIR3DL1HIGH/KIR3DL1NULL genotype were only signifi-
cant in individuals possessing Bw4 (Fig. 2).
Differential associations between KIR3DL1/S1 functional
genotypes and clinical manifestations of BD
The BD population was then split into two subgroups: those with
purely mucocutaneous (MC) disease (n = 166) and those with
ophthalmic involvement (n = 91). The MC and ophthalmic groups
did not significantly differ with regard to their ethnic makeup
(p = NS) (Fig. 1). The two groups were then compared with the
HC group. HLA-B*51 remained associated with BD in both
groups (MC group: p = 0.0009, OR 4.14, 95% CI 2.72–6.32;
ophthalmic group: p = 0.0367, OR 1.75, 95% CI 1.05–2.92),
and there was no difference between the groups with regard
to KIR3DL1/S1 presence/absence (data not shown). We were
unable to replicate the association between an increase in
KIR3DS1 alleles and ophthalmic involvement as was previ-
ously reported (26).
Examining KIR3DL1/S1 allele combinations in the MC group
revealed an increase in KIR3DL1*00701/KIR3DS1*013 compared
with HCs (p = 0.0071, OR 13.04, 95% CI 1.51–112.49). Despite
this, none of the functional genotypes were associated with
MC disease. Conversely, no specific combination of KIR3DL1/
S1 alleles conferred protection to MC disease, but the functional
FIGURE 1. The diagnosis of BD was made in a tertiary referral center by a multidisciplinary team, with experts from the following fields: oral medicine,
rheumatology, ophthalmology, neurology, immunology, and psychology. Percentage of the self-reported ethnicity can be seen next to each manifestation of
BD. The majority of patients presenting with MC disease, arthritis, and ocular disease were of Northern European ethnicity, in keeping with the overall
makeup of the cohort. Of note, increased percentages of Middle Eastern patients had vascular, neurologic, and gastrointestinal manifestations.
Table II. HLA-A and -B associations in the U.K. cohort
U.K. Cohort (HC n = 445, BD n = 267)
HLA Type HC (n) HC (%) BD (n) BD (%) p Value Pc OR 95% CI
Increased risk
HLA-B*51 62 6.97 67 12.55 0.0006 0.019 1.92 1.33–2.76
HLA-B*08 78 8.76 67 12.55 0.0238 NS 1.49 1.06–2.11
HLA-A*25 11 1.2 17 3.1 0.0121 NS 2.51 1.17–5.41
HLA-A*26 24 3.2 26 5.1 0.0291 NS 1.76 1.00–3.10
Reduced risk
HLA-B*58 16 1.80 2 0.37 0.0248 NS 0.21 0.05–0.90
HLA-A*33 36 4.3 10 2.3 0.0131 NS 0.45 0.22–0.92
Those in bold are significant (p , 0.05) results in which the 95% CI does not cross 1.
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genotype KIR3DL1HIGH/KIR3DL1NULL reduced the risk of developing
purely MC disease (p = 0.0048, OR 0.45, 95% CI 0.25–0.81).
The ophthalmic group had an increased frequency of
KIR3DL1*00501/KIR3DS1*013 (p = 0.0003, OR 3.27, 95% CI
1.65–6.48) and KIR3DL1*00701/KIR3DS1*013 (p = 0.0039, OR
18.83, 95% CI 2.08–170.47) compared with controls. Of note, the
functional genotype KIR3DL1LOW/KIR3DS1 conferred significant
risk (p = 1.2 3 1025, OR 3.92, 95% CI 2.06–7.47) in these in-
dividuals. There were no protective effects observed in this group
(Fig. 3).
Discussion
KIR expression is variable on individual NK cells, and this can have
a major influence on the response to immune challenge (37). We
have examined the risk alleles associated with BD in a large co-
hort of patients in the United Kingdom, the majority of whom are
of Northern European heritage. As expected, the strongest risk
association was found with HLA-B*51 with weaker associations
from HLA-B*08, HLA-A*25, and HLA-A*26. Protective effects
were identified from HLA-B*58 and HLA-A*33, confirming pre-
vious studies in European and Korean patients (38, 39).
As stated, KIR3DL1/S1 recognizes the Bw4 epitope at the C
terminus of the a-chains forming the peptide binding groove in a
subset of MHC class I molecules. As such, polymorphisms within
KIR3DL1/S1 can alter the strength of binding and thus the in-
hibitory potential of the KIR–HLA interaction.
Because of small sample numbers, some specific allele asso-
ciations did not remain significant after multiple testing [both
KIR3DL1*00501 and KIR3DS1*01301 showed a trend toward an
association with BD (Supplemental Table III)] but nevertheless
deserve further attention with a wider cohort and functional
studies.
The functional genotype results show an association between
a risk genotype made up of a KIR3DL1LOW allele (*00501 or
*00701) and the activating allele KIR3DS1*013 (KIR3DL1LOW/
KIR3DS1) and protective effects from the genotype made up of
KIR3DL1*0010101 and *00401 (KIR3DL1HIGH/KIR3DL1NULL).
In 2018, Martin et al. (40) described a single variant in KIR3DL1
that significantly modified progression of HIV-1 due to the pro-
tective response from HLA-B*57, supporting the concept of KIR/
HLA influencing disease outcome.
Despite many structural similarities between KIR3DL1 and
KIR3DS1, it remains contentious as to whether Bw4 is a ligand for
KIR3DS1. There has been one report of KIR3DS1 binding HLA-
B*57 (41) in the context of HIV-1 infection. More recently, HLA-
F was identified as a high-affinity ligand for KIR3DS1 (18).
HLA-F neither binds peptide nor requires b2-microglobulin to
fold stably. It is upregulated during cell stress (42) and has also
been implicated in NK cell education (19). HLA-F also binds
allotypes of KIR3DL1 but with a lower affinity. In BD, KIR3DS1
may recognize HLA-F that has been upregulated on lymphocytes
because of cell stress, leading to a persistent proinflammatory
state, which could be exacerbated by an immune “trigger” such as
a viral infection or mechanical trauma, downregulation of cell-
surface HLA, and increased cell-mediated cytotoxicity. This, in
conjunction with a KIR3DL1LOW allotype, may result in NK cells
that are more likely to degranulate than those without an inhibi-
tory KIR3DL1 or indeed an activating receptor. KIR3DS1 has also
been linked to a number of other diseases without a Bw4 asso-
ciation (43–45), suggesting that the effects of KIR3DS1 can be
Table III. The effects of the functional genotype KIR3DL1/S1 combinations
KIR3DL1HIGH–KIR3DL1 alleles are highly expressed and confer strong inhibition to cell-mediated lysis.
KIR3DL1LOW–KIR3DL1 alleles are expressed at a low level and confer weak inhibition to cell-mediated lysis.
KIR3DL1NULL–KIR3DL1*004 is mostly retained intracellularly and has minimal inhibitory potential. KIR3DS1
activates KIR allele. Those in bold signify significant (p , 0.05) results in which the 95% CI does not cross 1. Red
indicates an inhibitory KIR3DL1 allotype expressed at high levels on the cell surface, pink indicates an inhibitory
KIR3DL1 allotype expressed at low levels on the cell surface, yellow indicates a null KIR3DL1 allotype not expressed
on the cell surface, and green indicates an activating KIR3DL1 allotype.
Table IV. KIR3DL1 alleles that make up the risk and protective functional genotypes
A combination of the weakly expressed KIR3Dl1*005 and 007 were the KIR3DL1 alleles implicated in the risk genotype in
conjunction with KIR3DS1*013. The protective genotype was made up of highly expressed KIR3DL1*001 and KIR3DL1*004,
a null-expressing allele. Those in bold signify significant (p , 0.05) results in which the 95% CI does not cross 1. Red
indicates an inhibitory KIR3DL1 allotype expressed at high levels on the cell surface, pink indicates an inhibitory KIR3DL1
allotype expressed at low levels on the cell surface, yellow indicates a null KIR3DL1 allotype not expressed on the cell surface,
and green indicates an activating KIR3DL1 allotype.
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independent of Bw4. Similarly, the KIR3DL1LOW/KIR3DS1
functional genotype described in this study was found to be sig-
nificant in the Bw6 subgroup in addition to the Bw4 subgroup.
The protective KIR3DL1HIGH/KIR3DL1NULL genotype has no
activating KIR3D and thus relies on other activating receptors
to initiate degranulation. Why KIR3DL1HIGH/KIR3DL1NULL
should result in protection from disease whereas KIR3DL1HIGH/
KIR3DL1LOW/HIGH does not remains unclear. It may be that a
specific degree of KIR3DL1 surface tuning is required to provide
protective effects and that only KIR3DL1*004 is able to provide
this. It is also possible that only a small fraction of total
KIR3DL1*004 is required to interact with Bw4 to lead to down-
stream effects as previously suggested by the protective effects of
KIR3DL1*004 in HIV progression (46).
The role of KIR3DL1*004 in disease is of current interest.
Whereas KIR3DL1*004 was shown to be retained intracellularly
and not contribute to the inhibitory response (47), Taner et al. (46)
demonstrated that a small portion is correctly folded and cell
surface expressed. There is evidence to suggest that possession
of Bw4 and KIR3DL1*004 slows progression of HIV infection
to AIDS (48). Whether KIR3DL1*004 can be considered ‘null’
in the context of disease association is a subject for further
investigation.
Given the number of genetic risk factors uncovered by recent
GWAS, there are probably many different pathways, each with
small effects, that lead to the development of BD. The HLA–KIR
interaction may be a feasible biological explanation, but it fails to
explain the role of KIR3DL1/S1 in Bw42 patients with BD.
Whether there is an increased role for CD8 T cells–KIR interac-
tions in these individuals remains to be seen (49).
The putative hypothesis driving this project was that KIR3DL1
allotypes interact with Bw4 (and therefore HLA-B*51) at different
levels (31, 47) and thus may be implicated in disease pathogen-
esis. However, despite a strong HLA-B*51 association, there was
little evidence to suggest that the KIR3DL1/S1 genotype associa-
tions found in this study are mediated either by Bw4 or HLA-B*51
(Fig. 2). There are two possible explanations for this finding; first,
the mechanisms by which the KIR3DL1LOW/KIR3DS1 functional
genotype contribute toward disease risk are not directly due to an
inhibitory interaction between KIR3DL1-Bw4 but rather by in-
direct mechanisms. Whereas protective effects conferred from the
KIR3DL1HIGH/KIR3DL1NULL functional genotype are mediated
via a direct KIR3DL1–Bw4 interaction. Second, it may be that the
KIR3DL1–Bw4 interaction is integral to both risk and protective
effects but that there is a lack of power to detect the risk effects
within the HLA-B*51+ group. It should be noted that the
number of HLA-B*51+ individuals with either the risk or pro-
tective functional genotype was small, and this study is un-
likely to be sufficiently powered to exclude involvement of
HLA-B*51 in KIR3DL/S1 interactions. However, it is possible
that KIR3DL1/S1 is affecting disease susceptibility in ways
that are independent of Bw4. KIR3DL1–Bw4 interactions have
been extensively investigated and found to be highly variable,
depending both on the allotype of KIR3DL1 and on effects
outside the Bw4 binding site (50). These interactions are
complex and not easily studied in a project designed to analyze
the allelic variation of KIR3DL1.
BD is a heterogeneous condition. Many patients will only ever
experience orogenital ulceration, whereas others progress to de-
velop blinding uveitis or inflammatory brain disease. In this study,
two low-expressing KIR3DL1 alleles (*00501 and 00701) were
both found to confer risk in combination with KIR3DS1. In the
MC group, there was no effect from KIR3DL1*005, whereas in the
ophthalmic group, both alleles contributed to disease susceptibil-
ity. KIR3DL1*007 was found less frequently in both groups,
but its effect size was between 5 and 10 times greater than
KIR3DL1*005. KIR3DL1 comprises three ancestral lineages:
KIR3DS1*01301, KIR3DL1*005, and KIR3DL1*015 (47). From
these lineages, selection pressures have led to an abundance of
KIR3DL1 allotypes. The KIR3DL1*015 lineage is most diverse in
Africans, whereas the KIR3DL1*005 lineage is more common in
Caucasians (30). Whereas KIR3DL1*005 has remained stable for
more than three million years, KIR3DL1*007 segregated as a
clade from KIR3DL1*015 more recently. It is notable in our co-
hort that KIR3DL1*015 does not associate with BD, whereas
KIR3DL1*007 with its narrow binding pattern and KIR3DL1*005
with its broader specificity do. Despite these biological differ-
ences, both receptors are expressed at low levels on the cell sur-
face and confer weak inhibition of target cell lysis (51, 52).
Although this is the first study, to our knowledge, to examine
KIR3DL1/S1 alleles in BD, our findings correlate with published
data on other inflammatory diseases. In 2016, Ahn et al. examined
the frequency of KIR3DL1 allotypes in 203 patients with psoriasis
and 111 HC of European descent. Their results suggested that
the presence of a weakly inhibitory KIR3DL1 allotype increased
the risk of developing psoriasis, whereas KIR3DL1*004 was
protective (22). Similarly, Dı´az-Pen˜a et al. (53) found that the
FIGURE 2. Square markers represent “risk” genotypes, and circular
markers represent “protective” genotypes. The size of the markers are
proportional to the size of the subgroups. Points above the dotted line
represent the OR and 95% CIs for KIR3DL1LOW/KIR3DS1 risk group. Data
are shown (in descending order) for all individuals and then only those that
possess Bw4 (one or two copies), Bw6 (two copies), and HLA-B*51 (one
or two copies) and those that lack HLA-B*51. The points below the dotted
line represent the OR and 95% CIs for the protective genotype
KIR3DL1HIGH/KIR3DL1NULL with the same data groups.
FIGURE 3. Square markers represent risk genotypes, and circular
markers represent protective genotypes. The size of the markers are pro-
portional to the size of the subgroups. The protective KIR3DL1HIGH/
KIR3DL1NULL genotype was associated with a reduced risk of MC dis-
ease, whereas the risk KIR3DL1LOW/KIR3DS1 genotype was associated
with an increased risk of ophthalmic disease.
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combination of KIR3DS1*013 and KIR3DL1*004 protects against
ankylosing spondylitis.
Several other factors are involved in HLA-B*51 activity, in-
cluding endoplasmic reticulum aminopeptidase-1 (ERAP-1),
which cleaves peptides to fit into class I molecules. Polymor-
phisms in ERAP-1 have been associated with BD, and ERAP-1
variants influence the binding of a low affinity peptidome, which
may be relevant in BD (54, 55). Moreover, NK cells require only a
few degranulation events (around 10% of the total lytic granules)
to kill target cells. Such killing was dependent on the size of
granules and the speed at which they are released (56). Activating
and inhibitory KIR have been shown to have distinct nanocluster
formation on the cell surface controlled by their transmembrane
sequence. KIR2DS1 was found to have larger clusters than
KIR2DL1 and induce greater downstream signaling (57). Whether
KIR allotypes would influence these processes is a possible
mechanism to be investigated.
To conclude, this is the first study, to our knowledge, to analyze
the effect of KIR3DL1 allotypes in BD. We found HLA-B*51 to be
associated with BD in a large United Kingdom–based cohort and
confirm that HLA-A*26 is a risk allele in this population (58) and
found HLA-B*08 and A*25 are also implicated. We also confirm
that HLA-B*58 and HLA-A*33 are protective (38, 39). KIR3DL1
allele-level analysis revealed the KIR3DL1LOW/KIR3DS1 func-
tional genotype to be implicated in disease pathogenesis and
KIR3DL1HIGH/KIR3DL1NULL to be protective.
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